ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
kpax
|
8 |
1.3K |
5 |
24/05/24 |
24/05/24 |
ASX - By Stock
|
8
|
1.3K
|
5
|
|
ASX - By Stock
|
SNT |
Re:
SNT JustStocks Video on YouTube
|
|
kpax
|
34 |
6.3K |
0 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
34
|
6.3K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
SNT JustStocks Video on YouTube
|
|
kpax
|
34 |
6.3K |
3 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
34
|
6.3K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
kpax
|
251 |
53K |
51 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
251
|
53K
|
51
|
|
ASX - By Stock
|
SNT |
Syntara the science explained
|
|
kpax
|
8 |
1.3K |
11 |
23/05/24 |
23/05/24 |
ASX - By Stock
|
8
|
1.3K
|
11
|
|
ASX - By Stock
|
SNT |
Re:
SNT JustStocks Video on YouTube
|
|
kpax
|
34 |
6.3K |
6 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
34
|
6.3K
|
6
|
|
ASX - By Stock
|
SNT |
Re:
SNT JustStocks Video on YouTube
|
|
kpax
|
34 |
6.3K |
4 |
21/05/24 |
21/05/24 |
ASX - By Stock
|
34
|
6.3K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
kpax
|
251 |
53K |
11 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
251
|
53K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust receives Orphan Drug Designation for monepantel
|
|
kpax
|
43 |
11K |
36 |
18/05/24 |
18/05/24 |
ASX - By Stock
|
43
|
11K
|
36
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
kpax
|
250 |
60K |
14 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
60K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
kpax
|
250 |
60K |
15 |
12/05/24 |
12/05/24 |
ASX - By Stock
|
250
|
60K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Board Changes
|
|
kpax
|
250 |
60K |
12 |
11/05/24 |
11/05/24 |
ASX - By Stock
|
250
|
60K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
83 |
23K |
37 |
08/05/24 |
08/05/24 |
ASX - By Stock
|
83
|
23K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
kpax
|
239 |
62K |
17 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
239
|
62K
|
17
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
kpax
|
239 |
62K |
14 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
239
|
62K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
kpax
|
239 |
62K |
37 |
07/05/24 |
07/05/24 |
ASX - By Stock
|
239
|
62K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
Corporate action
|
|
kpax
|
239 |
62K |
30 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
239
|
62K
|
30
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
kpax
|
104 |
19K |
16 |
03/05/24 |
03/05/24 |
ASX - By Stock
|
104
|
19K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
kpax
|
104 |
19K |
25 |
02/05/24 |
02/05/24 |
ASX - By Stock
|
104
|
19K
|
25
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
24 |
01/05/24 |
01/05/24 |
ASX - By Stock
|
1.4K
|
353K
|
24
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Appendix 4C & Quarterly Update
|
|
kpax
|
104 |
19K |
47 |
30/04/24 |
30/04/24 |
ASX - By Stock
|
104
|
19K
|
47
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
19 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
1.4K
|
353K
|
19
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
51 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
1.4K
|
353K
|
51
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
kpax
|
1 |
930 |
4 |
05/04/24 |
05/04/24 |
ASX - By Stock
|
1
|
930
|
4
|
|
ASX - By Stock
|
PAA |
NZT gone but hasn't forgotten
|
|
kpax
|
66 |
18K |
62 |
03/04/24 |
03/04/24 |
ASX - By Stock
|
66
|
18K
|
62
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
kpax
|
126 |
32K |
20 |
23/03/24 |
23/03/24 |
ASX - By Stock
|
126
|
32K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
kpax
|
126 |
32K |
22 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
32K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at NWR Virtual Healthcare Conference
|
|
kpax
|
126 |
32K |
28 |
22/03/24 |
22/03/24 |
ASX - By Stock
|
126
|
32K
|
28
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
kpax
|
317 |
81K |
26 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
317
|
81K
|
26
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Positive clinical data filed with FDA to support ODD request
|
|
kpax
|
100 |
27K |
21 |
14/03/24 |
14/03/24 |
ASX - By Stock
|
100
|
27K
|
21
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
22 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
1.4K
|
353K
|
22
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
kpax
|
58 |
15K |
23 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
58
|
15K
|
23
|
|
ASX - By Stock
|
PAA |
Re:
Amylyx class action Relyvrio
|
|
kpax
|
58 |
15K |
32 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
58
|
15K
|
32
|
|
ASX - By Stock
|
PAA |
Amylyx class action Relyvrio
|
|
kpax
|
58 |
15K |
36 |
07/03/24 |
07/03/24 |
ASX - By Stock
|
58
|
15K
|
36
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
2 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.4K
|
353K
|
2
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
20 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
1.4K
|
353K
|
20
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
kpax
|
1.4K |
353K |
15 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
1.4K
|
353K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
18 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
18
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
38 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
38
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
27 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
27
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
kpax
|
114 |
33K |
56 |
26/02/24 |
26/02/24 |
ASX - By Stock
|
114
|
33K
|
56
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EGM Shareholder Presentation
|
|
kpax
|
45 |
13K |
35 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
45
|
13K
|
35
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
kpax
|
197 |
52K |
21 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
197
|
52K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Outlines Pathway to Accelerated Approval for MPL in MND
|
|
kpax
|
58 |
15K |
26 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
58
|
15K
|
26
|
|
ASX - By Stock
|
PAA |
Best ASX stock Pharmaust for the next 10 years
|
|
kpax
|
9 |
2.7K |
33 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
9
|
2.7K
|
33
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Extension Study Begins, Analysis Suggests Survival Benefit
|
|
kpax
|
197 |
52K |
37 |
14/02/24 |
14/02/24 |
ASX - By Stock
|
197
|
52K
|
37
|
|
ASX - By Stock
|
PAA |
Re:
MY INPUT REGARDING PAA AND SARS-COV-2.
|
|
kpax
|
41 |
9.2K |
12 |
06/02/24 |
06/02/24 |
ASX - By Stock
|
41
|
9.2K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
76K |
20 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
323
|
76K
|
20
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
76K |
12 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
76K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
kpax
|
323 |
76K |
12 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
76K
|
12
|
|